FHTXHealthcare · BiotechnologyThe 10 Wall Street analysts covering Foghorn Therapeutics, Inc. hold a median 12-month price target of $12 — +74.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 22 Aug 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Foghorn Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (87): Sales and profits are climbing, and climbing faster than before.
Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on FHTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +74.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Mar 2026 | Wedbush | Reiterates | Outperform | $10 |
| 10 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | $13 |
| 17 Feb 2026 | Jefferies | Maintains | Buy | — |
| 18 Dec 2025 | BTIG | Initiates | Buy | — |
| 4 Dec 2025 | Stifel | Initiates | Buy | — |
| 7 Nov 2025 | Guggenheim | Initiates | Buy | — |
| 15 May 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 30 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Apr 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 23 Apr 2025 | JMP Securities | Initiates | Market Outperform | — |
| 7 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Jan 2025 | B. Riley Securities | Initiates | Buy | — |
| 17 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Dec 2024 | Jefferies | Maintains | Buy | — |
| 24 Sept 2024 | Morgan Stanley | Maintains | Equal-Weight | — |
| 3 Sept 2024 | Jefferies | Initiates | Buy | — |
| 19 Aug 2024 | Evercore ISI Group | Initiates | Outperform | — |
| 12 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Aug 2024 | Wedbush | Reiterates | Outperform | — |
| 7 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FHTX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, Foghorn Therapeutics, Inc. returned +23.6% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 13% of US stocks
Cheaper than 97% of US stocks
Cheaper than 77% of US stocks
Higher than 94% of US stocks
Higher than 85% of US stocks
Higher than 16% of US stocks
Higher than 3% of US stocks
Higher than 94% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Foghorn Therapeutics, Inc. has a market value of $419.9M and an enterprise value of $295.4M.
Revenue in the twelve months to 30 June 2026: $36.7M. The latest quarter grew 112.7% year on year.
Net income over the same four quarters: −$64.6M, a −175.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$84.3M.
Trailing P/E: −6.0×; forward P/E: −6.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Foghorn Therapeutics, Inc. employs 106 people — $347K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Foghorn Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research published a piece examining whether Foghorn Therapeutics (FHTX) qualifies as a strong momentum stock for investors to consider.
Why it matters — The article suggests FHTX may be gaining favorable attention from momentum-focused market participants, which could influence near-term trading dynamics.
Wall Street analysts' mean price target for Foghorn Therapeutics implies roughly 88.5% upside in the stock. While that price-target metric has historically not proven highly reliable, analysts' strong agreement in raising earnings estimates is cited as a signal of potential upside.
Why it matters — FHTX watchers would care because analyst consensus, particularly the collective upward revision of earnings estimates, is being highlighted as a possible indicator of improvement in the company's prospects.
Foghorn Therapeutics reported a second-quarter loss of $0.10 per share, narrower than both the Zacks Consensus Estimate of a $0.23 loss and the $0.28 loss recorded a year earlier. The company also beat revenue estimates for the quarter.
Why it matters — The result shows FHTX outperformed analysts' expectations for the quarter, with a smaller loss than forecast and than the prior year.
Foghorn Therapeutics released its second-quarter 2026 financial and corporate update, reporting approximately $168 million in cash, cash equivalents, and marketable securities with a cash runway into the first half of 2028. The company noted progress on its FHD-909 Phase 1 dose-escalation trial targeting non-small cell lung cancer, and said it is advancing selective EP300 degraders and a novel oral small molecule in immunology/inflammation, each with INDs targeted for 2027.
Why it matters — The update confirms pipeline advancement across oncology and immunology programs and reassures FHTX watchers about an extended cash runway into the first half of 2028, reducing near-term funding pressure.
The 10 Wall Street analysts covering Foghorn Therapeutics, Inc. have a median 12-month price target of $12, with estimates ranging from $9 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Foghorn Therapeutics, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Foghorn Therapeutics, Inc. 72 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Foghorn Therapeutics, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +74.7% from the last close, and Ticker Nerd's factor model ranks Foghorn Therapeutics, Inc. 72 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Foghorn Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FHTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $14 over the next 12 months.
Foghorn Therapeutics, Inc. returned +23.6% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Foghorn Therapeutics is a clinical-stage biopharmaceutical company pioneering a new class of precision medicine therapeutics that treat serious diseases by correcting abnormal gene expression. The company uses its proprietary Gene Traffic Control platform to systematically identify, validate, and drug targets within the chromatin regulatory system, which orchestrates how genes turn on and off in cells.
The most recent item we track (Zacks Investment Research, 14 Aug 2026): "Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy". Zacks Investment Research published a piece examining whether Foghorn Therapeutics (FHTX) qualifies as a strong momentum stock for investors to consider.
Foghorn Therapeutics is a clinical-stage biopharmaceutical company pioneering a new class of precision medicine therapeutics that treat serious diseases by correcting abnormal gene expression. The company uses its proprietary Gene Traffic Control platform to systematically identify, validate, and drug targets within the chromatin regulatory system, which orchestrates how genes turn on and off in cells. Foghorn is advancing nearly 10 programs across multiple cancer types, including non-small cell lung cancer, prostate cancer, breast cancer, and various lymphomas and leukemias. Its lead clinical candidate, FHD-909, is a selective SMARCA2 inhibitor in Phase 1 development for SMARCA4-mutated cancers. The company is also developing selective degrader programs targeting CBP, EP300, and ARID1B for various malignancies. Headquartered in Cambridge, Massachusetts, Foghorn maintains strategic collaborations including a partnership with Eli Lilly and Company for developing oncology therapeutics. The company addresses a significant market need, as more than half of all cancers are associated with chromatin regulatory system abnormalities.
CEO Mr. Adrian H. B. Gottschalk · 106 employees · United States · https://foghorntx.com
